A new immune approach for preventing brain tumor recurrence
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
This research explores a new way to train the body's immune system to fight glioblastoma brain tumors and prevent them from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11124135 on NIH RePORTER |
What this research studies
Glioblastoma is a very aggressive brain tumor that often returns even after standard treatments. This project aims to develop a novel immune therapy that targets a protein called Fgl2, which helps tumors hide from the immune system. By blocking Fgl2, the goal is to activate special immune cells in the brain that can remember and destroy tumor cells. This approach could potentially clear remaining tumor cells and create long-lasting protection against recurrence.
Who could benefit from this research
Good fit: Patients with glioblastoma who have undergone standard chemotherapy might eventually be candidates for this type of immune therapy.
Not a fit: Patients with other types of brain tumors or those whose glioblastoma has not responded to initial treatments may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could offer a new treatment option to prevent glioblastoma from returning, potentially improving long-term outcomes for patients.
How similar studies have performed: This research builds on recent discoveries about Fgl2's role in glioblastoma and preliminary data showing promising results in animal models.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Li, Shulin — University of Tx Md Anderson Can Ctr
- Study coordinator: Li, Shulin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.